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Aim
To assess colorectal cancer (CRC) risk during colono-
scopy surveillance in a cohort of patients with the ser-
rated polyposis syndrome (SPS).
Method
Colonoscopy and histology records from January 2000
to time of interview for 67 New Zealand patients, meet-
ing WHO criteria for a diagnosis of SPS and enrolled in
the Genetics of Serrated Neoplasia study, were reviewed.
Polyp demographics, smoking status and family history
of cancer were recorded.
Results
Of 67 patients 18 presented with CRC (mean age 57yrs,
12 Female). Only one of 18 reported a first degree rela-
tive (FDR) with CRC. Over a median follow-up of 8
years from time of surgery with an average interval of
16 months between colonoscopies, two patients devel-
oped metachronous CRC: one identified at prophylactic
completion colectomy and one in association with first
diagnosis of SPS 19 yrs following initial CRC and 30
months after a previous colonoscopy. Of 45 patients
with polyps alone (mean age 48 yrs, 27 female) followed
for a median of 9 years with an average interval of 15
months between colonoscopies, none developed CRC
despite 33 having multiple pan colonic polyps. Of these
33, 70% had an adenoma, 18 % a sessile serrated polyp
and 53 % polyps >10 mm. A FDR with CRC was
reported in 14/45 (31%). Four patients with multiple
pan colonic polyps and no FDR with CRC underwent
prophylactic subtotal colectomy (mean age 58 yrs, 3
females) after being followed for a median of 5 years
with an average interval between colonoscopies of 8
months. All had adenomas and one a sessile serrated
polyp. No significant smoking effect was seen in any
group.
Conclusion
If endoscopic control is feasible, SPS patients can
be judiciously managed by frequent surveillance
colonoscopy.
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